NaF PET Imaging for Bone Cancer
Trial Summary
What is the purpose of this trial?
18F-sodium fluoride (18F-NaF) was already investigated numerous times in the last 40 years as a PET alternative to standard 99m-technetium-derived bone scintigraphy. However, lack of universal tracer availability and higher costs contributed to the failure of 18F-NaF to systematically supplant bone scintigraphy as a standard of care. Recently, an isotope shortage crisis occurred and evidenced the need to have non-reactor-derived alternatives for many nuclear medicine procedures, including bone scintigraphy. Since 18F-NaF is cyclotron-produced, it could become a necessary alternative to bone scintigraphy in case of another worldwide isotope shortage. The study aims to evaluate the safety profile of 18F-NaF injection. Moreover, a patient registry will be compiled in order to perform sub-studies on 18F-NaF diagnostic performance on diverse bone and articular diseases.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug 18F-sodium fluoride for bone cancer?
Research shows that 18F-sodium fluoride, when used in PET/CT scans, is highly effective in detecting bone metastases, which are cancerous growths that spread to the bones. This drug provides clearer and more accurate images compared to older methods, helping doctors make better treatment decisions for patients with bone cancer.12345
Is 18F-NaF PET imaging safe for humans?
18F-NaF PET imaging has been used for many years and is considered safe for humans. It was approved by the U.S. Food and Drug Administration in 1972 and is known for its rapid clearance from the blood and high uptake in bones, which makes it effective for imaging without significant safety concerns.12367
How is the drug 18F-NaF different from other treatments for bone cancer?
18F-NaF PET/CT is unique because it offers higher sensitivity and specificity in detecting bone metastases compared to traditional bone scans, and it provides rapid imaging with better patient convenience. This drug is a positron-emitting agent that allows for high-quality imaging of the skeleton, making it particularly effective for assessing both malignant and benign bone diseases.12368
Eligibility Criteria
This trial is for patients who need a bone scan (99mTc-biphosphonate bone scintigraphy) due to conditions like infections, arthritis, or bone tumors. It includes adults and children with cancer or infectious diseases needing this test. Pregnant individuals, those allergic to 18F-NaF, or unable to lie flat for at least 15 minutes cannot participate.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 18F-NaF PET scans as an alternative to standard 99mTc bone scintigraphy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 18F-sodium fluoride (Radiopharmaceutical)
18F-sodium fluoride is already approved in United States, European Union for the following indications:
- Bone metastasis detection
- Skeletal imaging for benign and malignant disorders
- Bone metastasis detection
- Skeletal imaging for benign and malignant disorders